Revista medica de Chile最新文献_第10页

[Asthma as a Protective Factor Against Mortality in Mexican Population with COVID-19]. [哮喘是墨西哥人口 COVID-19 死亡率的保护因素]。

Revista medica de Chile Pub Date : 2023-11-01 DOI: 10.4067/s0034-98872023001101437

I A Roy-García, J A Ortega-Martell, I Palma-Lara, D A Herrera-Sánchez, S M Sánchez-Morales, R Rivas-Ruiz

{"title":"[Asthma as a Protective Factor Against Mortality in Mexican Population with COVID-19].","authors":"I A Roy-García, J A Ortega-Martell, I Palma-Lara, D A Herrera-Sánchez, S M Sánchez-Morales, R Rivas-Ruiz","doi":"10.4067/s0034-98872023001101437","DOIUrl":"https://doi.org/10.4067/s0034-98872023001101437","url":null,"abstract":"Background: SARS-CoV-2 infection associated with the presence of comorbidities increased the risk of mortality. However, the role of asthma as a predictor of mortality and severity has not been defined.Aim: To assess the impact of asthma as a factor associated with the decrease in mortality in the Mexican population with COVID-19.Methodology: We performed a cross-sectional and secondary analysis of the database of the General Directorate of Epidemiology of the Mexican Government, updated to May 2023. The analysis included the Mexican population with a confirmed diagnosis of SARS-CoV-2 by RT-PCR.Results: A total of 617,367 participants were included, with a mean age of 36. Mortality was 0.9%, 0.2% required admission to the intensive care unit (ICU). The prevalence of asthma in this population was 1.9%. When performing the multivariate logistic regression analysis, we found that the presence of asthma decreased the risk of mortality, with an OR of 0.57 (95% CI 0.45, 0.72; p = < 0.001). The variables of age > 60 years, smoking, arterial hypertension, Diabetes, Chronic Obstructive Pulmonary Disease (COPD), cardiovascular disease, and chronic kidney disease (CKD) were factors associated with an increase in mortality. The diagnosis of asthma was not associated with mechanical ventilation or ICU admission.Conclusion: The presence of asthma in patients with COVID-19 decreased the risk of mortality by 43%. The immunological context could explain the decreased risk of mortality in asthmatic patients infected with SARS-CoV-2.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 11","pages":"1437-1445"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Prevalence of frailty in the different regions of Chile: A cross-sectional analysis of the National Health Survey 2016-2017]. [智利不同地区的虚弱患病率：2016-2017年全国健康调查横断面分析]。

Revista medica de Chile Pub Date : 2023-11-01 DOI: 10.4067/s0034-98872023001101506

Claudia Troncoso-Pantoja, Felipe Díaz-Toro, Fanny Petermman-Rocha, Carlos Celis-Morales, Yeny Concha-Cisternas, Gabriela Nazar, Ana María Leiva-Ordoñez, María Adela Martinez-Sanguinetti, Igor Cigarroa

{"title":"[Prevalence of frailty in the different regions of Chile: A cross-sectional analysis of the National Health Survey 2016-2017].","authors":"Claudia Troncoso-Pantoja, Felipe Díaz-Toro, Fanny Petermman-Rocha, Carlos Celis-Morales, Yeny Concha-Cisternas, Gabriela Nazar, Ana María Leiva-Ordoñez, María Adela Martinez-Sanguinetti, Igor Cigarroa","doi":"10.4067/s0034-98872023001101506","DOIUrl":"https://doi.org/10.4067/s0034-98872023001101506","url":null,"abstract":"Frailty is an increasingly frequent geriatric syndrome in the population; however, its regional prevalence in Chile has not been quantified.Aim: To determine the prevalence of frailty according to Chile's regions, using the Frailty Index (IF).Material and methods: In this cross-sectional study, data from 3,036 participants with 40 or more years of the National Health Survey 2016-17 were used. For the measurement of frailty, we created a 49-item IF, and everyone was given a score from 0 to 1. Based on the score obtained, we categorized the participants as: «robust», «pre-frail», and «frail». The prevalence was calculated and divided according to geographical areas (North, Center, and South), considering the 15 regions of Chile in force as of 2016.Results: At the national level, the prevalence of robust, pre-frail, and frail individuals was 47,6%, 40,6%, and 11,8%, respectively. 15,9% were women and 7,4% men; 18,9% of the sample had less than eight years of education. The Libertador General Bernardo OHiggins Region showed a higher prevalence of frailty (18,3%), followed by the Maule Region (16,7%), which also had a higher prevalence of pre-frailty (49,6%). The Tarapacá Region presented a higher prevalence of robust people (64,6%).Conclusions: The prevalence off rail individuals was higher in the central zone of Chile, it increased as age increased, and it was higher in women with a lower educational level.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 11","pages":"1506-1512"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The power of collaboration: Ultrasonographic screening by family physicians in primary health care for early evaluation of chronic kidney disease"]. [合作的力量：家庭医生在初级卫生保健中进行超声波筛查以早期评估慢性肾病"]。

Revista medica de Chile Pub Date : 2023-11-01 DOI: 10.4067/s0034-98872023001101551

Hans Müller-Ortiz, Cristian Pedreros-Rosales, Patricia Villaseca-Silva, Lesly Costa Cornejo

引用次数: 0

[Polymorphic lymphoproliferative disorder, lymphomatoid granulomatosis-type, in a patient with iatrogenic immunosuppression, an unusual entity]. [一名先天性免疫抑制患者的多形性淋巴组织增生性疾病，淋巴瘤样肉芽肿病型，一个不寻常的实体]。

Revista medica de Chile Pub Date : 2023-11-01 DOI: 10.4067/s0034-98872023001101532

Cristián Vargas, Marcelo Abarca, Eduardo Rojas, Verónica Wolff, Cristina Fernández, María Teresa Rivera, Céfora Suárez, Pablo Villegas, Macarena Roa, Camila Peña

{"title":"[Polymorphic lymphoproliferative disorder, lymphomatoid granulomatosis-type, in a patient with iatrogenic immunosuppression, an unusual entity].","authors":"Cristián Vargas, Marcelo Abarca, Eduardo Rojas, Verónica Wolff, Cristina Fernández, María Teresa Rivera, Céfora Suárez, Pablo Villegas, Macarena Roa, Camila Peña","doi":"10.4067/s0034-98872023001101532","DOIUrl":"10.4067/s0034-98872023001101532","url":null,"abstract":"Patients with immunodeficiency, whether congenital or acquired, have a significantly higher incidence of malignancies, especially mature lymphoid neoplasms and lymphoproliferative disorders. We present the case of a 50-year-old patient with a history of dermatomyositis and antisynthetase syndrome on immunosuppressive therapy, who consulted due to increased volume of the lacrimal gland in the upper left eyelid, associated with weight loss and night sweats. He was admitted for an elective biopsy. The day after the postoperative period, she evolved with an acute abdomen. Computed axial tomography revealed multiple hypodense lesions in the liver, spleen, kidneys, and adrenal glands associated with a perforated tumor in the transverse colon and free fluid in the peritoneal cavity. In this scenario, an infectious, neoplastic, or rheumatological etiology was considered a differential diagnosis, especially in the context of our patient. Finally, the biopsies evidenced extensive necrosis with angiocentric and angiodestructive lymphoid infiltration associated with positive EBV. After extensively reviewing the symptoms, histology, and new classifications of mature B-lymphoid neoplasms, the diagnosis of polymorphic B-lymphoproliferative disorder, lymphomatoid granulomatosis-type was made, an uncommon entity rarely associated with iatrogenic immunosuppression.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 11","pages":"1532-1537"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Local advances and challenges in the molecular diagnosis of solid tumors: a health perspective towards precision oncology in Chile]. [实体瘤分子诊断的本地进展与挑战：智利精准肿瘤学的健康视角]。

Revista medica de Chile Pub Date : 2023-10-01 DOI: 10.4067/s0034-98872023001001344

Katherine Marcelain, Carolina Selman-Bravo, Benjamín García-Bloj, Eva Bustamante, Jorge Fernández, Fancy Gaete, Leonor Moyano, Juan Carlos Bustos, Francisca Plaza-Parroquia, Juan A Godoy, Marcelo Garrido, Tomás P Labbé, Juvenal A Ríos

{"title":"[Local advances and challenges in the molecular diagnosis of solid tumors: a health perspective towards precision oncology in Chile].","authors":"Katherine Marcelain, Carolina Selman-Bravo, Benjamín García-Bloj, Eva Bustamante, Jorge Fernández, Fancy Gaete, Leonor Moyano, Juan Carlos Bustos, Francisca Plaza-Parroquia, Juan A Godoy, Marcelo Garrido, Tomás P Labbé, Juvenal A Ríos","doi":"10.4067/s0034-98872023001001344","DOIUrl":"https://doi.org/10.4067/s0034-98872023001001344","url":null,"abstract":"Cancer will remain one of the most significant challenges for public health, locally and globally. Currently, cancer is the leading cause of death in our country. Thanks to the enormous knowledge accumulated in recent decades on the cellular and molecular bases of cancer, precision oncology has been developed, an approach that allows for increasingly precise pharmacological treatment based on diagnostic tests. Advanced technologies such as next-generation sequencing are used for this purpose. It is essential to implement these technologies in current and future health systems to optimize the arsenal of strategies for cancer control. This review discusses some of the achievements of precision oncology, particularly applied to solid tumors. It addresses the state-of-the-art minimum biomarkers required for the diagnosis of this important group of neoplasms, the local situation regarding technological capabilities installed in the national territory, either for research or diagnosis, and the potential health impact of applying all this practical knowledge to serve people with cancer, both in the public and private sectors.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 10","pages":"1344-1360"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Clinical experience of using brentuximab-vedotin as therapy in relapsed/refractory Hodgkin's lymphoma at Hospital Guillermo Grant Benavente, Concepción, Chile]. [智利康塞普西翁吉列尔莫-格兰特-贝纳文特医院使用布仑妥昔单抗-维多汀治疗复发/难治性霍奇金淋巴瘤的临床经验]。

Revista medica de Chile Pub Date : 2023-10-01 DOI: 10.4067/s0034-98872023001001361

Catalina Vidal, Fernanda Figueroa, Vania Briones, Vicente Micolich, Mauricio Chandia

{"title":"[Clinical experience of using brentuximab-vedotin as therapy in relapsed/refractory Hodgkin's lymphoma at Hospital Guillermo Grant Benavente, Concepción, Chile].","authors":"Catalina Vidal, Fernanda Figueroa, Vania Briones, Vicente Micolich, Mauricio Chandia","doi":"10.4067/s0034-98872023001001361","DOIUrl":"https://doi.org/10.4067/s0034-98872023001001361","url":null,"abstract":"Introduction: Hodgkin's lymphoma is a B-cell neoplasm with a good prognosis but a poor response to chemotherapy in refractory or relapsed cases. Brentuximab-vedotin is an anti-CD30 monoclonal antibody approved for use in these cases. This study aims to describe the clinical experience of patients treated with brentuximab-vedotin through expanded access modality.Materials and methods: A retrospective study on clinical information of patients diagnosed with refractory or relapsed Hodgkin's lymphoma treated with brentuximab-vedotin at the Regional Hospital of Concepción in the period 2015-2021.Results: 7 patients were identified, 5/7 male, with a median age of 35 years (21-50). Five cases were mixed cellularity, and two were nodular sclerosis. Four were in stage II, 1/7 in stage III, and 3/7 in stage IV. The median number of previous treatment lines was 4 (3-5), and the relapse was post-transplantation in two cases. In 6/7 cases, brentuximab-vedotin was used as induction, and in one case, it was used as post-autologous bone marrow transplant maintenance. The administration was outpatient via a peripheral route with a median dose of 150 mg and ten cycles. In one case, dose adjustment was required due to toxicity. Three out of 6 patients achieved complete remission and underwent autologous stem cell transplantation.Conclusion: brentuximab-vedotin is an outpatient medication with low toxicity that can optimize the treatment of patients with relapsed-refractory Hodgkin's lymphoma.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 10","pages":"1361-1366"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infectious disease evaluations in a psychiatric unit, an observational study. 精神病院的传染病评估，一项观察性研究。

Revista medica de Chile Pub Date : 2023-10-01 DOI: 10.4067/s0034-98872023001001271

Alberto Fica, Luis Gálvez, Esteban Teneb, Cristian Fernandoi, Sergio Acevedo

{"title":"Infectious disease evaluations in a psychiatric unit, an observational study.","authors":"Alberto Fica, Luis Gálvez, Esteban Teneb, Cristian Fernandoi, Sergio Acevedo","doi":"10.4067/s0034-98872023001001271","DOIUrl":"https://doi.org/10.4067/s0034-98872023001001271","url":null,"abstract":"Patients in adult psychiatric wards present infectious complications or pathologies that mimic an infectious condition, and there is little information on this subject.Objectives: To know the frequency and infectious and non-infectious complications treated by infectious disease specialists in a psychiatric intensive-care hospitalization unit for adults and their outcomes.Methods: Observational study between 2016 and 2021.Results: 37 patients with 41 events were evaluated. Almost half of the visits to these events originated from an antimicrobial stewardship program (46.3%). In 68.3% of the events, complementary studies were requested; in 14.6%, referral to other specialties; in 26.8%, an antimicrobial treatment was started; and in 75%, modifications were made to previous schemes. An infectious cause was identified in 30 of 41 events (73.2%) that included the following conditions: respiratory (31.7%), skin (9.8%), urinary (7.3%), gynecological (2.4%), one case of bacteremia with unknown source (2.4%), sequential infections (4.9%) and HIV therapy dropouts (7.3%). In the 11 remaining events, non-infectious causes were identified (26.8%): pulmonary thromboembolism, drug hepatotoxicity, false positive VDRL and HIV tests, steroid-induced psychosis in an HIV patient with thrombocytopenia, fever without etiology, residual positive SARS-CoV-2 PCR test, low O2 pulse oximetry due to oversedation and neuroleptic malignant syndrome. There was no mortality.Conclusions: Patients in psychiatric hospitalization wards suffer from a great diversity of infectious problems during their stay with conditions that simulate infections. An antibiotic surveillance system can detect half of these conditions. The infectious diseases visits allow for advising or reorienting of the study and modifying the antibiotic treatment.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 10","pages":"1271-1280"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis]. [西泊尼莫德（BAF312）：药物基因组剂量在治疗活动性继发性进行性多发性硬化症中的一般特征和临床意义]。

Revista medica de Chile Pub Date : 2023-10-01 DOI: 10.4067/s0034-98872023001001375

Susan Calfunao, Matías Carrasco, Carolina Gutierrez, Leslie Cerpa, Nelson Varela, Luis Quiñones

{"title":"[Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis].","authors":"Susan Calfunao, Matías Carrasco, Carolina Gutierrez, Leslie Cerpa, Nelson Varela, Luis Quiñones","doi":"10.4067/s0034-98872023001001375","DOIUrl":"https://doi.org/10.4067/s0034-98872023001001375","url":null,"abstract":"Siponimod is a selective immunosuppressive medication, developed as the first oral therapy for active secondary progressive multiple sclerosis. This medication acts by modulating the sphingosine 1 phosphate (S1P) receptor, as an antagonist of S1P1 and S1P5, thus preventing the egress of lymphocytes from lymph nodes and preventing inflammatory processes in the Central Nervous System that trigger demyelination. There is extensive scientific knowledge regarding the administration of the medication to patients, which will depend on their pharmacogenetic characteristics. Therefore, the FDA strongly recommends conducting a genotyping study of the enzyme that metabolizes siponimod, CYP2C9, whose genetic variants *2 and *3 classify patients as poor, extensive, or rapid metabolizers. Siponimod is completely contraindicated for patients who are homozygous for CYP2C9*3. Additionally, before prescribing it, an electrocardiogram, assessments of antibody status, ophthalmic evaluation, varicella vaccination status, and peripheral lymphocyte count should be conducted, as the medication's effect is dose-dependent. Therefore, a titration process is carried out starting from 0.25mg up to 2 mg. The pharmacotherapeutic protocol of siponimod is a reliable reflection of the utility of pharmacogenetics in personalized medicine.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 10","pages":"1375-1384"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Barrett's Esophagus: Update on the Diagnosis and Treatment. Review]. [巴雷特食道：诊断和治疗的最新进展。评论]。

Revista medica de Chile Pub Date : 2023-10-01 DOI: 10.4067/s0034-98872023001001332

Alberto Espino, José Ignacio Vargas, Gonzalo Latorre, Hugo Richter, Nicolás Quezada, Javiera Torres, Adolfo Parra-Blanco

{"title":"[Barrett's Esophagus: Update on the Diagnosis and Treatment. Review].","authors":"Alberto Espino, José Ignacio Vargas, Gonzalo Latorre, Hugo Richter, Nicolás Quezada, Javiera Torres, Adolfo Parra-Blanco","doi":"10.4067/s0034-98872023001001332","DOIUrl":"https://doi.org/10.4067/s0034-98872023001001332","url":null,"abstract":"Barrett's esophagus (BE) is the condition in which a metaplastic columnar mucosa predisposed to neoplasia replaces the squamous mucosa of the distal esophagus. The current guidelines recommends that diagnosis requires the finding of intestinal metaplasia (IM) with goblet cells of at least 1 cm in length. BE affects approximately 1% of the general population and up to 14% of patients with gastroesophageal reflux disease (GERD). BE is a precursor of esophageal adenocarcinoma (EAC), which has increased in western countries. The main risk factors described for EAC associated with BE are male sex, age > 50 years, central obesity and tobacco use. Annual risk of EAC in patients with BE without dysplasia, low grade (LGD) and high-grade dysplasia is 0,1-0,3%, 0,5% y 5-8%, respectively. Treatment of non-dysplastic BE consists mainly of a healthy lifestyle change, chemoprevention with proton pump inhibitors and surveillance endoscopy every 3 to 5 years. It is recommended that from the presence of LGD patients are referred to an expert center for confirmation of the diagnosis, stage and thus define their management. In patients with BE and dysplasia or early-stage cancer, endoscopic therapy with resection and ablation is successful in about 90% of the patients. The main adverse event is esophageal stricture, which is managed endoscopically.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 10","pages":"1332-1343"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determination of associated factors with death in Staphylococcus aureus bacteremia in hospitalized patients during the COVID-19 pandemic: A single-center, retrospective study. 确定 COVID-19 大流行期间住院病人金黄色葡萄球菌菌血症死亡的相关因素：单中心回顾性研究。

Revista medica de Chile Pub Date : 2023-10-01 DOI: 10.4067/s0034-98872023001001319

Gulsah Tuncer, Ceyda Geyiktepe-Guclu, Serkan Surme, Osman Faruk Bayramlar, Betul Copur, Yusuf Emre Ozdemir, Kadir Gorkem Guclu, Filiz Pehlivanoglu, Gonul Sengoz, Mustafa Yildirim

{"title":"Determination of associated factors with death in Staphylococcus aureus bacteremia in hospitalized patients during the COVID-19 pandemic: A single-center, retrospective study.","authors":"Gulsah Tuncer, Ceyda Geyiktepe-Guclu, Serkan Surme, Osman Faruk Bayramlar, Betul Copur, Yusuf Emre Ozdemir, Kadir Gorkem Guclu, Filiz Pehlivanoglu, Gonul Sengoz, Mustafa Yildirim","doi":"10.4067/s0034-98872023001001319","DOIUrl":"https://doi.org/10.4067/s0034-98872023001001319","url":null,"abstract":"The effect of COVID-19 on the outcomes of patients with Staphylococcus aureus bacteremia is still unknown.Aim: In this study, we aimed to determine associated factors for mortality in patients with S. aureus bacteremia and to explore the impact of prior COVID-19.Design and setting: In this retrospective and single-center study, all adult patients (≥ 18 years old) with S. aureus bacteremia between March 2020 and February 2022 were included.Methods: The outcomes of our study were 14-day and 28-day hospital mortality after the first positive blood culture was obtained. Univariate and Cox regression analyses were performed.Results: A total of 140 patients with S. aureus bacteremia were included in the study. The median age was 64.5 (48.5-76) and 82 (58.5%) of the patients were male. 14-day and 28-day mortality rates were 28.6% and 37.1% respectively. Among patients with S. aureus bacteremia and previous COVID-19 history, 14-day and 28-day mortality rates were 33.9% (n = 21) and 41.9% (n = 26), respectively. Cox regression analysis revealed that Pitt bacteremia score, AST, urea, and previous antibiotic use were associated factors for 14-day mortality and 28-day mortality due to S. aureus bacteremia.Conclusions: This study justified the remarkable fatality of S. aureus bacteremia during the COVID-19 pandemic period and revealed that a high Pitt bacteremia score, increased levels of AST and urea, and previous antibiotic exposure were associated factors for mortality in patients with S. aureus bacteremia.","PeriodicalId":101370,"journal":{"name":"Revista medica de Chile","volume":"151 10","pages":"1319-1331"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0